AP NEWS

BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call

November 6, 2018

ALAMEDA, Calif.--(BUSINESS WIRE)--Nov 6, 2018--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has changed the time of its previously announced conference call to discuss its third quarter 2018 financial and operating results. BioTime management will be hosting the call on Thursday, November 8 th, 2018, at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time.

Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”. A live webcast of the conference call will be available online in the Investors section of BioTime’s website. A replay of the webcast will be available on BioTime’s website for 30 days and a telephone replay will be available through November 15 th, 2018, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and entering conference ID number 8658619.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen ®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime’s lead cell delivery clinical program is Renevia ®, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit  www.biotime.com  or connect with the company on Twitter, LinkedIn, FacebookYouTube, and  Google+. To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list:  http://news.biotime.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20181106005939/en/

CONTACT: BioTime Inc. IR

Ioana C. Hone, 510-871-4188

ir@biotimeinc.com

or

Solebury Trout IR

Gitanjali Jain Ogawa, 646-378-2949

Gogawa@troutgroup.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS MEDICAL DEVICES

SOURCE: BioTime Inc.

Copyright Business Wire 2018.

PUB: 11/06/2018 04:30 PM/DISC: 11/06/2018 04:30 PM

http://www.businesswire.com/news/home/20181106005939/en

AP RADIO
Update hourly